This trial is testing whether a beta blocker called carvedilol can help protect the hearts of breast cancer patients taking trastuzumab-based HER2-directed therapy, either by starting it when significant heart function decline or early signs of heart injury are noted, or preventatively before beginning trastuzumab-based therapy.
2 Primary · 2 Secondary · Reporting Duration: 2 years
Active Control
Experimental Treatment
450 Total Participants · 3 Treatment Groups
Primary Treatment: Carvedilol · No Placebo Group · Phase 2
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: